【Pfizer And Zai Lab Have Reached A Cooperation Agreement For The New Antibacterial Drug Dingo Lida In Mainland China.】On November 21, Pfizer And Zai Lab Announced A Global Strategy For The New Antibacterial Drug Dingo Lida (sulbactam Sodium-dalbavancin Sodium) In Mainland China, With A Subsidiary Of Pfizer Being Exclusively Responsible For The Commercialization Operation Of The Product In Mainland China. The New Antibacterial Drug Dingo Lida Is Currently The Only Antibacterial Drug Specifically Developed For The Treatment Of Carbapenem-resistant Acinetobacter Baumannii (CRAB). The Product Was Approved In 2023 And 2024 In The USA And Mainland China, Respectively

Quick Access to 7x24

Quick Access to More Editor-selected Real-time News

Exclusive video for free

Live Learn project team is dedicated to create exclusive videos

Real-time Quotes

View more faster market quotes

More comprehensive macro data and economic indicators

Members have access to entire historical data, guests can only view the last 4 years

Member-only Database

Comprehensive forex, commodity, and equity market data